French EMOSIS SAS announces opening of subsidiary in Israel

Emosis SAS, is opening a subsidiary in Israel. This new business entity, Emosis Ltd, headquartered in Tel Aviv, will be mostly dedicated to research and development of novel assays complementing the mother company existing technology platform and test portfolio. Emosis Ltd will also, when relevant, locally support commercialization and sales development of Emosis kits.
This strategic move starts building Emosis international footprint. Emosis will benefit from tremendous opportunities by being part of an exceptionally dynamic and innovative ecosystem that is directly connected with the major international players of the biomedical and healthcare innovation, most notably from the US and China.
Dr Frederic Allemand, co-founder of Emosis SAS and member of the Board of Emosis Ltd, commented: “We are very glad to start expanding our operations internationally with the opening of Emosis Ltd., and to have Aurore Andre, who is very much involved within the Israeli biomedical innovation community, to be in charge of Emosis Ltd corporate development.”
“It is my great pleasure to lead the corporate development of Emosis within the Start-Up Nation, renown for excellence in biomedical science and innovation. We will establish alliances and collaborations with Israeli scientific institutions and excellence centers in order to strengthen Emosis leadership in cell-based hemostasis testing,” added Aurore Andre, CEO of Emosis Ltd.
Emosis SAS, a French MedTech company founded early 2015 by Prof Aaron Tomer and Dr Frederic Allemand, to address largely unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders – hemostasis and thrombosis in medical parlance. Emosis uniquely applies, in a user-friendly way, the power of flow cytometry technology within the emerging paradigm of cell-based hemostasis – or cell-based coagulation, to enlighten medical decision of the physicians managing those patients.